Meeting
2013 ASCO Annual Meeting
A phase I study of sorafenib with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): Safety and efficacy results.
Authors
Jean Alfred Maroun
The Ottawa Hospital Cancer Center, Ottawa, ON, Canada
Jean Alfred Maroun , Derek J. Jonker , M. Christine Cripps , Timothy R. Asmis , Rakesh Goel , Rachel Anne Goodwin , Horia Marginean
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00780169
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3633)
DOI
10.1200/jco.2013.31.15_suppl.3633
Abstract #
3633
Poster Bd #
13C
Abstract Disclosures
Similar Posters
Poster
2012 Gastrointestinal Cancers Symposium
Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy.
First Author: Li-Tzong Chen
Poster
2018 Gastrointestinal Cancers Symposium
A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study.
First Author: Shigenori Kadowaki
Poster
2014 Gastrointestinal Cancers Symposium
A phase I/II study of cetuximab (cet) in combination with S-1 and oxaliplatin (SOX) in first-line treatment for metastatic colorectal cancer (mCRC) (JACCRO CC-06).
First Author: Akihito Tsuji
Poster
2023 ASCO Annual Meeting
Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.
First Author: David S. Hong